Skip to main content

Table 1 Demographic, HCV and HUV related characteristics of study patients

From: Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment

Factor

Total cohort (n = 103)

Peg-IFN + RBV

(n = 19)

Peg-IFN + RBV + TPV (n = 23)

IFN-free DAA (n = 61)

P value*

Age in years, mean (SD)

49.7 (9.3)

43.6 (12.1)

45.3 (7.8)

53.2 (7.0)

< 0.001

 Sex

  Female

7 (6.8%)

2 (11%)

3 (13%)

2 (3%)

0.17

  Male

96 (93.2%)

17 (89%)

20 (87%)

59 (97%)

Race

 Non-white

27 (26.2%)

5 (26%)

6 (26%)

16 (26%)

1.00

 White

76 (73.8%)

14 (74%)

17 (74%)

45 (74%)

Ethnicity

 Not hispanic

85 (82.5%)

14 (74%)

17 (74%)

54 (89%)

0.14

 Hispanic

18 (17.5%)

5 (26%)

6 (26%)

7 (11%)

HIV risk factor

 MSM

24 (23.3%)

4 (21%)

3 (13%)

17 (28%)

0.55

 Heterosexual

1 (1.0%)

0 (0%)

0 (0%)

1 (2%)

 Hemophilia

6 (5.8%)

0 (0%)

3 (13%)

3 (5%)

 MSM + IDU

45 (43.7%)

11 (58%)

11 (48%)

23 (38%)

 Heterosexual IDU

27 (26.2%)

4 (21%)

6 (26%)

17 (28%)

CD4 + in cells/mm3, median (IQR)

476.0 (341, 693)

607.0 (419, 719)

584.0 (426, 772)

417 (306, 598)

0.045

HIV viral load in copies/mL

 ≤ 50

94 (91.3%)

17 (89%)

20 (87%)

59 (97%)

1.00

 > 50

9 (8.7%)

5 (26%)

6 (26%)

16 (26%)

HCV viral load in millions IU/L, median (IQR)

2.0 (0.4, 5.8)

3.8 (0.3, 9.7)

3.6 (1.2, 17)

1.3 (0.4, 3.5)

0.017

HCV genotype

 1/1A/1B

86 (83.5%)

13 (68%)

23 (100%)

50 (83%)

0.014

 2

4 (3.8%)

1 (5%)

0 (0%)

3 (5%)

 3

11 (10.7%)

5 (26%)

0 (0%)

6 (10%)

 4

2 (1.9%)

0 (0%)

0 (0%)

2 (3%)

HCV treatment history

 Naïve

80 (77.7%)

19 (100%)

16 (70%)

45 (74%)

0.19

 IFN-intolerant

6 (5.8%)

0 (0%)

1 (4%)

5 (8%)

 Relapser

10 (9.7%)

0 (0%)

5 (22%)

5 (8%)

 Null responder

6 (5.8%)

0 (0%)

1 (4%)

5 (8%)

 Cure but reinfected

1 (1.0%)

0 (0%)

0 (0%)

1 (2%)

Cirrhosis status

 Non-cirrhotic

70 (68.0%)

17 (89%)

17 (74%)

36 (59%)

0.032

 Cirrhotic

33 (32.0%)

2 (11%)

6 (26%)

25 (41%)

Prior decompensation or CPS > B

 Compensated cirrhosis

20 (19.4%)

2 (11%)

4 (17%)

14 (23%)

0.13

 Prior decompensated cirrhosis

13 (12.6%)

0 (0%)

2 (9%)

11 (18%)

 Non-cirrhotic

70 (68.0%)

17 (89%)

17 (74%)

36 (59%)

SVR on treatment 1

 Yes

78 (76.5%)

12 (63%)

13 (57%)

53 (88%)

1.00

 No, null response

7 (6.9%)

2 (11%)

5 (22%)

0 (0%)

 No, relapse

4 (3.9%)

3 (16%)

0 (0%)

1 (2%)

 No, sides effects/adverse events

9 (8.8%)

2 (11%)

5 (22%)

2 (3%)

 No, died during treatment

4 (3.9%)

0 (0%)

0 (0%)

4 (7%)

Discontinuation due to severe adverse events (1st regimen)

 No

93 (91.2%)

17 (89%)

18 (78%)

58 (97%)

0.021

 Yes

9 (8.8%)

2 (11%)

5 (22%)

2 (3%)

 No. HCV-SI observations, median (IQR)

7.0 (4.0, 12.0)

8.0 (6.0, 15.0)

15.0 (11.0, 20.0

5.0 (4.0, 7.0)

< 0.001

Barriers to care

 Ongoing drugs/alcohol use

30 (29%)

8 (42%)

7 (30%)

15 (25%)

0.34

 Active psychiatric disease

28 (27%)

8 (42%)

6 (26%)

14 (23%)

0.26

 Unstable housing

5 (5%)

1 (5%)

3 (13%)

1 (2%)

0.10

  1. Peg-IFN Pegylated interferon, IFN Interferon, RBV Ribavirin, DAA Direct acting antiviral, MSM Men who have sex with men, IDU Intravenous drug use, HCV Hepatitis C virus, SVR Sustained viral response, CPS Child–Pugh score, SD Standard deviation, IQR Interquartile range, HCV-SI Hepatitis C symptom inventory
  2. * P value for comparison of the 3 groups: Peg-IFN + RBV vs. Peg-IFN + RBV + TPV vs. IFN-Free DAA